BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study

2018324 citationsJournal Articlehybrid Open Access

Authors

Thomas Kaley · Cornell University

Mehdi Touat

Vivek Subbiah

Antoine Hollebecque

Jordi Rodón · Vall d'Hebron Hospital Universitari

A. Craig Lockhart · University of Miami

Vicki L. Keedy · Vanderbilt University Medical Center

Franck Bielle

Ralf‐Dieter Hofheinz

Abstract

Vemurafenib demonstrated evidence of durable antitumor activity in some patients with BRAFV600-mutant gliomas, although efficacy seemed to vary qualitatively by histologic subtype. Additional study is needed to determine the optimal use of vemurafenib in patients with primary brain tumors and to identify the mechanisms driving differential responses across histologic subsets.

Topics & Keywords

Glioma Diagnosis and Treatment Melanoma and MAPK Pathways Cancer Mechanisms and Therapy

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 36, Issue 35, pp. 3477-3484

DOI: 10.1200/jco.2018.78.9990

Field-Weighted Citation Impact: 18.34

Command Palette

BRAF Inhibition in <i>BRAF</i><sup>V600</sup>-Mutant Gliomas: Results From the VE-BASKET Study

Authors

Abstract

Topics & Keywords

UN Sustainable Development Goals

Publication Details